ADC Therapeutics received accelerated approval for its drug from the FDA.
10 reports, 2 independent
Updated Nov 3
Gone quiet
- Reports
- 10
- Developments
- 3
- Repetition
- 70%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ADC Therapeutics received accelerated approval for its drug from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ADC Therapeutics secured conditional approval for its drug from the European Commission.1 source
ADC Therapeutics also began using LinkedIn and received conditional approval from the EC.1 source
ADC Therapeutics received accelerated FDA approval for its drug.1 source
Keep exploring
Part of
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Also in this story
- Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
The entities involved
-
ADC Therapeutics
company in Épalinges, Switzerland
Nothing else this week.
- FDA
Related events
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA granted accelerated approval for VOCERYQ, causing INOVIO stock to lead Nasdaq gainers.
Coverage
Newest first; wire copies grouped- prnewswire.com
- prnewswire.com
- prnewswire.com
- PR NewswireADC Therapeutics Makes Grants to New Employees Under Inducement Plan LAUSANNE, Switzerland, Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pionee
- PR NewswireADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 LAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and
- PR NewswireADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-st
- PR NewswireADC Therapeutics Makes Grants to New Employees Under Inducement Plan LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer
- Unknown outlet